LONDON (Alliance News) - Medical technology firm Angle PLC on Friday welcomed research presented at the National Cancer Research Institute annual conference which supported the use of the London firm's Parsortix cell separation technology.
Research carried out by the Barts Cancer Institute at Queen Mary University backed the use of Parsortix, Angle's liquid biopsy system, as part of a simple blood test to diagnose and monitor patients with prostate cancer.
The scientists from Barts were able to capture a specific sub-set of circulating tumour cells from prostate cancer patient blood samples which cannot be captured by traditional systems but which are linked to the spread of the disease.
"This is a significant milestone, which further supports the adoption of Parsortix as a non-invasive alternative to the biopsy of prostate tissue," said Angle Chief Executive Andrew Newland.
"Aside from being non-invasive, Parsortix has the potential to provide the additional staging information to allow physicians to determine which patients require treatment and to provide active monitoring for all prostate cancer patients," he added.
Angle shares were up 2.6% to 60.00 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Angle (AGL)